drugset / Trial / NCT02046174

Open-Label Phase IIb Efficacy Trial of Cancer Macrobeads Compared to Best Supportive Care in Colorectal Cancer Patients

NCT02046174 ↗

Phase 2 Completed 70 enrolled The Rogosin Institute Vital Systems Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a clinical research study of an investigational (FDA IND-BB 10091) treatment for patients with advanced colorectal cancer that no longer responds to standard therapies. The treatment is being evaluated for its effect on tumor growth. It consists of the placement (implantation) of small beads that contain mouse renal adenocarcinoma cells (RENCA macrobeads). The cells in the macrobeads produce substances that have been shown to slow or stop the growth of tumors in experimental animals and veterinary patients. It has been tested in 31 human subjects with different types of cancers in a Phase I safety trial. Phase II studies in patients with colorectal, pancreatic or prostate cancers are in progress

Timeline

Start
2014-04-03
Primary completion
2018-10-22
Completion
2018-10-22

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject RENCA macrobeads Unknown 8 unknown Other

Indications